Routine hepatitis B immunisation in India: cost-effectiveness assessment.
Based on World Bank guidelines, hepatitis B immunization would be an excellent public health investment, saving each life year for well below the per-capita gross domestic product. This would be one of the most cost-effective investments India could make in the field of health.
Miller
M A
MA
Research Fogarty International Center NIH, Bethesda, MD 20892-2220, USA. millermark@who.ch
Kane
M
M
D002648:Child; D003362:Cost-Benefit Analysis; D017325:Hepatitis B Vaccines / Q000191:economics*; D006801:Humans; D017589:Immunization Programs; D007194:India
D017325:Hepatitis B Vaccines